Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 art units • 5 examiners • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Takara Bio Usa Inc. has 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 7 pending office actions are distributed among 5 distinct examiners, showing that some examiners are managing multiple cases for the company. The portfolio is also spread across 4 distinct art units, indicating a variety of technical focuses within the biotechnology field.
LU, FRANK WEI MIN is the busiest examiner for this company, with 3 busiest examiner pending actions. These 3 busiest examiner pending actions are part of the 7 pending office actions currently active. The involvement of 5 distinct examiners across 4 distinct art units suggests that the company must adapt to several different examination styles. For the 7 pending office actions, the company's strategy involves interacting with 4 distinct art units, which likely have different internal standards. This distribution of 5 distinct examiners means that LU, FRANK WEI MIN has a significant role, handling 3 busiest examiner pending actions.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (29%) |
| §102 only | 1 (14%) |
| §112 only | 2 (29%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LU, FRANK WEI MIN | 3 | 62.7% | +67.9% |
| GROSS, CHRISTOPHER M | 1 | 63.5% | +40.2% |
| BERA, HENA RAKESHKUMAR | 1 | 100.0% | +0.0% |
| BERTAGNA, ANGELA MARIE | 1 | 44.7% | +46.3% |
| CHUNDURU, SURYAPRABHA | 1 | 53.3% | +17.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18519715 | Device for Liquid Handling | BERA, HENA RAKESHKUMAR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17401662 | Methods for Adding Adapters to Nucleic Acids and Compositions for Practicing the Same | BERTAGNA, ANGELA MARIE | 5d |
| 16963365 | Methods of Amplifying Nucleic Acids and Compositions and Kits for Practicing the Same | CHUNDURU, SURYAPRABHA | 30d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17980848 | Methods for Adding Adapters to Nucleic Acids and Compositions for Practicing the Same | LU, FRANK WEI MIN | 17d overdue |
| 17401662 | Methods for Adding Adapters to Nucleic Acids and Compositions for Practicing the Same | BERTAGNA, ANGELA MARIE | 5d |
| 17955938 | Methods of Depleting a Target Molecule from an Initial Collection of Nucleic Acids, and Compositions and Kits for Practicing the Same | LU, FRANK WEI MIN | 20d |
| 16963365 | Methods of Amplifying Nucleic Acids and Compositions and Kits for Practicing the Same | CHUNDURU, SURYAPRABHA | 30d |
| 19363300 | Methods for Adding Adapters to Nucleic Acids and Compositions for Practicing the Same | LU, FRANK WEI MIN | — |
| 18291773 | Methods and Compositions for Producing Cell-Source Identifiable Collections of Nucleic Acids | GROSS, CHRISTOPHER M | — |
| Art Unit | Apps |
|---|---|
| 1683 | 3 |
| 1681 | 2 |
| 1684 | 1 |
| 1798 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19363300 | Methods for Adding Adapters to Nucleic Acids and Compositions for Practicing the Same | LU, FRANK WEI MIN | 1683 | §103 | Final Rejection | — | Pending | Oct 20, 2025 |
| 18291773 | Methods and Compositions for Producing Cell-Source Identifiable Collections of Nucleic Acids | GROSS, CHRISTOPHER M | 1684 | §102 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18519715 | Device for Liquid Handling | BERA, HENA RAKESHKUMAR | 1798 | §103 | Final Rejection | — | Pending | Nov 27, 2023 |
| 17980848 | Methods for Adding Adapters to Nucleic Acids and Compositions for Practicing the Same | LU, FRANK WEI MIN | 1683 | §112 | Final Rejection | 17d overdue | Pending | Nov 04, 2022 |
| 17955938 | Methods of Depleting a Target Molecule from an Initial Collection of Nucleic Acids, and Compositions and Kits for Practicing the Same | LU, FRANK WEI MIN | 1683 | §112 | Non-Final OA | 20d | Pending | Sep 29, 2022 |
| 17401662 | Methods for Adding Adapters to Nucleic Acids and Compositions for Practicing the Same | BERTAGNA, ANGELA MARIE | 1681 | §102§103 | Final Rejection | 5d | Pending | Aug 13, 2021 |
| 16963365 | Methods of Amplifying Nucleic Acids and Compositions and Kits for Practicing the Same | CHUNDURU, SURYAPRABHA | 1681 | §103§112 | Non-Final OA | 30d | Pending | Jul 20, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTakara Bio Usa Inc. has 7 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Frank Wei Min Lu has the most, with 3 of Takara Bio Usa Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
